Ifosfamide nephropathy in patients with sarcoma.

Area of Science:

• Oncology
• Nephrology
• Pharmacology

Background:

• Ifosfamide is a key alkylating agent for sarcoma treatment.
• Major ifosfamide toxicities include nephropathy, neuropathy, and hematologic complications.
• This study focuses on ifosfamide-induced nephropathy in sarcoma patients.

Purpose of the Study:

• To determine the frequency and severity of ifosfamide nephropathy.
• To analyze renal side effects in patients receiving ifosfamide for sarcoma.

Main Methods:

• Ninety sarcoma patients (52 male, 38 female) treated with ifosfamide were analyzed.
• Data included physical exams, lab results, and glomerular filtration rate.
• Follow-up duration ranged from 6 to 12 months.

Main Results:

• Renal side effects observed: proteinuria (15.5%), microscopic hematuria (14.4%), glycosuria (7.8%), and elevated serum creatinine (2.2%).
• A combination of proteinuria and glycosuria occurred in 5.5% of patients.
• No gross hematuria was reported, but microscopic hematuria was present in 14.4%.

Conclusions:

• Ifosfamide nephropathy presents with varying severity in sarcoma patients.
• Current monitoring protocols for ifosfamide side effects may require adjustments for different patient populations.